NCT00722293: A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors |
|
|
| Completed | 1 | 111 | Europe | Doxorubicin, Pazopanib (GW786034), Epirubicin | GlaxoSmithKline | Neoplasms, Breast | 06/12 | 02/14 | | |
NCT00822848: Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma |
|
|
| Completed | 1 | 18 | US | epirubicin hydrochloride, ifosfamide, sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, Adjuvant radiotherapy, Adjuvant chemotherapy, neoadjuvant therapy, Neoadjuvant chemoradiotherapy, therapeutic conventional surgery, hypofractionated radiation therapy | OHSU Knight Cancer Institute, National Cancer Institute (NCI) | Sarcoma | 09/12 | 04/13 | | |